INVESTIGATIVE REPORT

Investigation of Cytomegalovirus and Human Herpes Viruses 6 and 7 as Possible Causative Antigens in Psoriasis

B. KIRBY1, O. AL-JIFFRI2, R. J. COOPER2, G. CORBITT2, P. E. KLAPPER2 and C. E. M. GRIFFITHS1

1Dermatology Centre, University of Manchester, Hope Hospital, Salford and 2Virology Division, School of Medicine, University of Manchester, Manchester Health Care Trust, Manchester, UK

Psoriasis is probably a T-cell-mediated autoimmune disease. Infectious models of autoimmune diseases have been proposed and in psoriasis, it has been suggested that there may be molecular mimicry between streptococcal antigens and epidermal keratins. The immunological profile of stable psoriasis plaques suggests, however, that viral antigens may be important. We investigated, using polymerase chain reaction techniques, whether DNA from either cytomegalovirus (CMV) or human herpes viruses (HHV) 6 and 7 is present in the skin of patients (n= 10) with chronic plaque psoriasis. We also investigated 29 patients for the presence of serum IgG to CMV. We found no evidence of CMV or HHV 7 DNA in psoriasis plaques although DNA for HHV 6 was detected in both involved and uninvolved skin in 1 out of 10 patients. There was no statistically significant increase in prior CMV infection, as assessed by the presence or absence of serum IgG to CMV, in psoriasis, compared to our local population. Although there is circumstantial evidence that viral antigens may be important in the pathogenesis of psoriasis we found no evidence to link infection with CMV or HHV 6 and 7 with subsequent development of chronic plaque psoriasis. Key words: Th1 cytokines; Vβ restriction; polymerase chain reaction.

(Accepted September 13, 2000.)

Acta Derm Venereol 2000; 80: 404±406

Professor CEM Griffiths, Dermatology Centre, University of Manchester, Hope Hospital, Salford M6 8HD, UK.
E-mail: egriffiths@fs1.ho.man.ac.uk

Although the ultimate pathogenesis of psoriasis remains unclear, there is strong evidence suggesting it to be a T-cell-mediated autoimmune disease (1). Immunohistochemically, psoriatic plaques are characterized by a predominantly dermal infiltration of CD4+ T cells and intraepidermal CD8+ T cells (1, 2). These T cells produce multiple cytokines, mainly in a Th1 (interferon-γ and interleukin-2) profile (3). Classically, the stimulation of CD8+ T cells with production of Th1 cytokines occurs in response to intracellular bacterial and viral antigens (4). Recently it has been shown that there is clonal expansion of certain subsets of CD8+ T cells within psoriatic plaques (2). These T cells appear to respond in an antigen-specific manner (5). Viral antigens have been proposed as important in the immunopathogenesis of both type I diabetes mellitus (6) and multiple sclerosis (7, 8). These diseases share similar immunological features to those of psoriasis, which include: (i) Vβ restriction of T-cell receptors; (ii) a T-cell predominant inflammatory infiltrate in the target organ; (iii) a local excess of Th1 cytokines; and (iv) development of the disease is dependent on interactions between a genetic predisposition and environmental factors (6–8).

Any virus proposed as a candidate aetiologic agent for psoriasis would need to (i) be common; (ii) have a predominantly asymptomatic primary infection; (iii) possess the ability to remain latent and to reactivate within the host; (iv) be capable of being detected in skin; and (v) be able to induce a local inflammatory response. Human herpes viruses (HHV) 6 and 7 and cytomegalovirus (CMV) commonly produce chronic, asymptomatic infections and may cause local immune-mediated reactions (9, 10). CMV can stimulate local production of tumour necrosis factor-α and interleukin-2 (11), both of which are increased in psoriatic plaques (1, 3). Infection with HHV 6 and 7 is ubiquitous and the majority of infections are asymptomatic (9, 10). Furthermore, HHV 6 has been implicated in the pathogenesis of roseola and multiple sclerosis (9).

We hypothesize that the psoriatic phenotype may occur as the result of an immune reaction to normally asymptomatic local viral, or similar, infection in genetically predisposed individuals. We therefore investigated whether patients with chronic plaque psoriasis exhibit evidence of infection with CMV and HHV 6 and 7.

MATERIAL AND METHODS

Patients aged ≥18 years with chronic plaque psoriasis were recruited from our psoriasis clinic. After written informed consent (approved by the Salford and Trafford Local Research Ethics Committee) blood was taken from 29 patients. Ten other patients had 4 mm diameter punch skin biopsies (using lignocaine and adrenaline as local anaesthetic) taken from involved and uninvolved skin. None of the patients were on systemic therapy or receiving phototherapy for psoriasis. Serum antibodies to CMV (IgG) were measured by ELISA. Infection with HHV 6 and 7 is ubiquitous by adulthood and therefore serological tests for antibodies to these organisms were not performed. Biopsies from involved and uninvolved skin were examined for DNA of CMV, HHV 6 and 7.

Skin biopsies were initially snap-frozen in liquid nitrogen and stored at ~80 C. The biopsies were disrupted during thawing by using a glass homogenizer. DNA was extracted from this material with guanidine thiocyanate and isopropanol precipitation. The sequences of the human CMV primers were 5'-TGCGATGATGTTCCCT- TAAAG-3' (H23C) and 5'AAAGATCAGCTAGCTGGTTTATT- CCTA-3' (H66C) and 5'CTCGAGTGATGGCAGACCCCTAATGTT- GCAAGAGTATTACAC-3' (HV-11) (14), with a product size of 123 bp. The β-globin primers were 5'-
GAAGGCGAAGGAAGGTAC-3' (GH20) and 5'CAACTT-CATCCACGTTC ACC-3' (PC04) (15), with a product size of 268 bp.

The PCR mixture comprised 10 mM Tris/HCl (pH 8.3), 1.5 mM MgCl$_2$, 50 mM KCl, 200 μM each deoxynucleoside triphosphate, 0.2 μM each of the appropriate primers, 1.25 U of AmpliTag Gold polymerase (Perkin-Elmer, Akron, OH) and 5 μl of appropriate DNA sample to a final volume of 50 μl. Every PCR run included a contamination control, where sterilized, distilled water replaced the DNA sample, and an extraction control, where sterilized, distilled water was extracted alongside the specimens and added to a PCR mix. Each reaction mixture was overlaid with one drop of mineral oil to prevent evaporation. An initial denaturing step at 94°C for 9.9 min was followed by 40 cycles at 94°C (1 min), 55°C (1 min) and 72°C (1 min) on a PHC-1 thermal cycler (Techne, Cambridge, UK). The amplification products were analysed by ethidium bromide staining after electrophoresis in 6% polyacrylamide gels and the anti-contamination measures were as described previously (16). These included separate rooms for preparation of the reaction mixtures and for preparation and addition of DNA extracts and a third room for product analysis. Plugged pipette tips were used throughout.

Positive control DNA comprised: (a) human genomic DNA (Boehringer, Roche Diagnostics, UK); (b) the HindIII restriction fragment J of HCMV (AD169) DNA cloned into plasmid pAT153 (15); and (c) the HindIII restriction fragment pHDX5 of HHV 6 DNA (17) and HHV 7-infected cell DNA (Abgene, Epsom, UK).

Using these control DNAs, the β-globin and HHV 6 PCRs had sensitivities of ~10 copies per reaction mixture, the CMV PCR could detect 10–100 copies and the HHV 7 PCR could detect a 10$^{-6.5}$ dilution of HHV 7-infected cell DNA. For HHV 6-positive samples, 5 μl of reaction product was digested overnight with 5 units of AvaII (Boehringer) according to the manufacturer’s instructions (17). The products were analysed by polyacrylamide gel electrophoresis.

RESULTS

Twenty-one of 29 (72%) patients had IgG antibodies to CMV, compared with 50% in our general control population (18). Antenatal screening has suggested that the incidence of CMV infection increases by 1% per year after adolescence (19). As the mean age of our population was 44.6 ± 10.8 years (range 23–69 years), there was thus no significant increase in CMV infection in our patients with psoriasis. There was no correlation between infection with CMV, clinical severity of psoriasis and previous treatment with systemic therapy. CMV DNA was detected in both the involved and uninvolved skin of 10 patients. DNA for HHV 6 subgroup A was detected in both the involved and uninvolved skin in 1 of the 10 patients.

DISCUSSION

Infectious models for the pathogenesis of autoimmune diseases have been proposed previously and several studies of diabetes (6) and multiple sclerosis (7, 8) have supported this hypothesis. Such an infectious model has been proposed for psoriasis in relation to streptococcal infection, with possible molecular mimicry between the streptococcal M-peptide and keratins (20). While streptococcal keratin mimicry may play a role in the development of psoriatic plaques, the immunological characteristics of such plaques suggest that other factors may be important. These immunological characteristics include: (i) Vβ restriction of T cells within psoriatic plaques; (ii) a predominantly Th1 cytokine profile; and (iii) activated CD8+ T cells. All of these factors are indicative of an immunological response to the presence of local stimulating viral or intracellular bacterial antigens (4, 5). There is circumstantial evidence to support this concept, which includes the observations that zidovudine and hydroxyurea, agents with anti-retroviral activity (21), are effective in treating psoriasis. Furthermore, there is evidence that DNA of human immunodeficiency virus (22), hepatitis C virus (23) and human papillomavirus (24) is present in psoriatic plaques.

We investigated whether CMV or HHV 6 and 7 are possible causative or contributory antigens in psoriasis. We chose these viruses because infection with them is common and because HHV 6 has been proposed as a possible antigen in multiple sclerosis, which shares several immunological characteristics with psoriasis. HHV 7 and CMV are similar viruses to HHV 6 and can also evoke immunological reactions (11). Although a recent study (25) found evidence of increased CMV antigenemia in psoriasis, there was no evidence of CMV antigens in the skin. As CD8+ T cells in psoriasis appear to act in an antigen-specific manner, the absence of CMV antigens in the skin would suggest that CMV infection is not a primary event in either the development or maintenance of psoriasis plaques. The presence of HHV 6 DNA in the skin of only 1 of our patients suggests that this organism is unlikely to be of significance. It has been suggested that multiple sclerosis is a manifestation of several disease processes (8). Similarly, psoriasis may be considered as a final cutaneous manifestation of several pathomechanistic processes. These processes could include persistent viral infection of the skin resulting in skin homing of specific CD8+ T cells and subsequent release of cytokines, growth factors and angiogenic factors by both activated T lymphocytes and keratinocytes. Potential viral candidates as antigens for psoriasis would have to be common, capable of causing an immunological reaction and present in skin. Future studies will concentrate on searching for likely viral candidates for psoriasis.

In conclusion, there is circumstantial evidence that local viral or intracellular bacteria may be responsible for the immunological events seen in chronic plaque psoriasis. However, we have shown that infection with CMV and HHV 6 and 7 is unlikely to play an important role in psoriasis pathogenesis. Candidate infectious agents which may be important to investigate include retroviruses, Coxsackie viruses and Epstein–Barr virus.

REFERENCES

1. Valdimarsson H, Baker BS, Jonsdottir I, Powles AV, Fry L. Psoriasis: a T-cell mediated autoimmune disease induced by streptococcal superantigens? Immunol Today 1995; 16: 145–149.
2. Chang JCC, Smith LR, Froning JK, Schwabe BJ, Laxer JA, Carali LL, et al. CD8+ T cells in psoriatic lesions preferentially use T cell receptor Vβ3 and/or Vβ13.1 genes. Proc Natl Acad Sci USA 1994; 91: 9282–9286.
3. Schlaak JF, Buslau M, Jochum W, Hermann E, Girndt M, Gallati H, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102: 145–149.
4. Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999; 20: 147–161.
5. Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gurtler L, et al. Evidence for an antigen specific cellular immune

Acta Derm Venereol 80
response in skin lesions of patients with psoriasis vulgaris. J Immunol 1995; 155: 4078–4083.
6. Bertera S, Alexander A, Giannoukakis N, Robbins PD, Trucco M. Immunology of type 1 diabetes. Intervention and prevention strategies. Endocrinol Metab Clin N Am 1999; 28: 841–864.
7. Bar-Or A, Oliveira EM, Anderson DE, Hafer DA. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol 1999; 100: 252–259.
8. Hafer DA. The distinction blurs between an autoimmune versus microbial hypothesis in multiple sclerosis. J Clin Invest 1999; 104: 527–529.
9. Dockrell DH, Smith TF, Puya CV. Human herpes virus 6. Mayo Clin Proc 1999; 74: 163–170.
10. Berneman ZN, Ablashi DV, Li G, Eger-Fletcher M, Reitz MS Jr, Hung CL, et al. Human herpesvirus 7 is T-lymphotropic and is related to, but significantly different from, human herpes virus 6 and cytomegalovirus. Proc Natl Acad Sci USA 1992; 89: 10552–10556.
11. Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S. Role of infection as a risk factor for atherosclerosis, myocardial infarction and stroke. Clin Infect Dis 1998; 26: 719–734.
12. McElhinney LM, Cooper RJ, Morris DJ. Multiplex polymerase chain reaction for human herpes virus-6, human cytomegalovirus and human beta-globin DNA. J Virol Methods 1995; 53: 223–233.
13. Gopal MR, Thomson BJ, Fox J, Tedder RS, Honess RW. Detection by: PCR of HHV-6 and EBV DNA in blood and oropharynx of healthy adults and HIV positives. Lancet 1990; i: 1598–1599.
14. Morris DJ, Bailey AS, Cooper RJ, Turner PC, Jackson R, Corbitt G, et al. Polymerase chain reaction for rapid detection of ocular adenovirus infection. J Med Virol 1995; 46: 126–132.
15. Oram JD, Downing RG, Akrigg A, Dollery AA, Duggleby CJ, Wilkinson GWG, et al. Use of recombinant plasmids to investigate the structure of the human cytomegalovirus genome. J Gen Virol 1982; 59: 111–129.
16. Martin ME, Thomson BJ, Honess RW. The genome of human herpes virus-6: maps of unit length and concatemeric genomes for nine restriction enzymes. J Gen Virol 1991; 72: 157–168.
17. Kidd IM, Clark DA, Bremner JAG, Pillay D, Griffiths PD, Emery VC. A multiplex PCR assay for the simultaneous detection of human herpes virus 6 and human herpes virus 7, with typing of HHV-6 by enzyme cleavage of PCR products. J Virol Methods 1998; 70: 29–36.
18. Klapper PE, Cleator GM, Prinja-Wilks D, Morris DJ, Morell G. Immunoradiometric assay for cytomegalovirus-specific IgG antibodies: assay development and evaluation in blood transfusion practice. J Virol Methods 1990; 27: 327–339.
19. Griffiths PD, Baboonian C. A prospective study of primary cytomegalovirus during pregnancy: final report. Br J Obstet Gynaecol 1984; 91: 307–315.
20. Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H, Jonsdottir I. Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis? Clin Exp Immunol 1999; 117: 580–586.
21. Lisziewcz J, Jessen J, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998; 352: 199–200.
22. Mahoney SE, Duvic M, Nickoloff BJ, Minshall M, Smith LC, Griffiths CE, et al. Human immunodeficiency virus (HIV) transcripts identified in HIV-related psoriasis and Kaposi’s sarcoma lesions. J Clin Invest 1991; 88: 174–185.
23. Yamamoto T, Katayama I, Nishioka K. Psoriasis and hepatitis C virus. Acta Derm Venereol 1995; 75: 482–483.
24. Favre M, Orth G, Majewski S, Bavul S, Pura A, Jablonska S. Psoriasis: a possible reservoir for human papilloma virus type 5, the virus associated with skin carcinoma of epidermodysplasia verruciformis. J Invest Dermatol 1998; 110: 311–318.
25. Asadullah K, Prosch S, Audring H, Buttenrova I, Volk HD, Sterry W, et al. A high prevalence of cytomegalovirus antigenemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor alpha overexpression. Br J Dermatol 1999; 141: 94–102.